Chemomab Therapeutics (CMMB) announced results from the Open Label Extension portion of the Phase 2 SPRING trial assessing nebokitug as a ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and Biomea Fusion (NASDAQ:BMEA – Get Free Report) are both small-cap ...

Mirum Pharmaceuticals, Inc. shows strong growth with a 43% revenue jump and promising pipeline assets. Click here for my ...

BiomX (NYSEAMERICAN:PHGE – Get Free Report) is anticipated to announce its earnings results before the market opens on ...

As the Boston Athletic Association's first official charity team, ALF has a long history in Boston. Since 1988, the American Liver Foundation Maratho ...

Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...

Mirum Pharmaceuticals, Inc. today announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI® ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.

Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...